





























Link to publication record in King's Research Portal
Citation for published version (APA):
Jauhar, S., & Howes, O. D. (2019). Understanding and Predicting Variability in Response to Treatment in
Psychotic Disorders: In Vivo Findings. Clinical Pharmacology and Therapeutics, 105(5), 1079-1081.
https://doi.org/10.1002/cpt.1357
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
 1 
 "Understanding and predicting variability in response to treatment in psychotic disorders: 
in vivo findings" 
Authors: Sameer Jauhar1,2, Oliver D Howes3,4,5 
1. Department of Psychological Medicine, Institute of Psychiatry, Psychology and 
Neuroscience, King’s College, London 
2. Early Intervention Psychosis Clinical Academic Group, South London & Maudsley NHS 
Trust, London. 
3. Psychiatric Imaging Group MRC London Institute of Medical Sciences, Hammersmith 
Hospital, London, W12 0NN, UK 
4. Department of Psychosis Studies, Institute of Psychiatry, Psychology and 
Newuroscience, King’s College, London. SE5 8AF 
5. Institute of Clinical Sciences, Faculty of Medicine, Imperial College, Hammersmith 
Hospital, London, W12 0NN, UK 
 
 
Corresponding Author: Profesdor Oliver Howes; Box 63, Institute of Psychiatry, Camberwell, 
London, SE5 8AF, UK. Tel: +44208 383 3446; email: oliver.howes@kcl.ac.uk 
 
Keywords: dopamine, positron emission tomography, antipsychotic drugs, psychosis, F-
DOPA, schizophrenia. 
 
Number of words in the main text; 1550 











Psychotic illnesses such as schizophrenia and bipolar affective disorder are severe mental 
disorders characterised by delusions and hallucinations. They have a lifetime prevalence of 
approximately 3%, and are associated with decreased life expectancy of 15-20 years 
compared to the general population; highlighting the importance of patients receiving 
effective treatment. 
The main treatment for psychosis is antipsychotic medication, both for acute psychotic 
episodes and relapse prevention. These drugs are effective; showing an average pooled 
effect size for psychotic symptom reduction of around 0.5 for acute episodes. However, this 
belies striking variability in response between individuals: some patients show dramatic 
improvement, whilst others show little or no change in symptoms.  
The last decade has seen the field increasingly recognize symptom reduction on a rating 
scale may not translate into meaningful clinical improvements. Studies indicate that a 
decrease of at least 30% in psychotic symptom severity is the minimum clinically meaningful 
change. Unfortunately, about 1 in 3 patients do not experience clinically meaningful 
response to first-line antipsychotics, termed treatment resistance. Treatment resistance is 
seen in around 15-20% of people with schizophrenia from illness onset; and develops over 
time in a further 15% whose illness initially responded to antipsychotic treatment.  
There is currently only one drug licensed in treatment resistant schizophrenia, clozapine. 
Whilst clozapine leads to symptomatic and functional improvements, and reduced 
mortality, use is limited by risk of potentially life-threatening side-effects. Therefore, it is 
important to ensure psychosis is unlikely to respond to other drugs before introducing 
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clozapine. Recognition of this has led to a focus on understanding causes of variability in 
treatment response, and developing biomarkers to guide treatment choice. 
Pseudo-treatment resistance 
In clinical practice some people are given diagnoses of treatment resistant illness when 
other factors account for lack of response, “pseudo-treatment resistance.” These include 
poor oral antipsychotic concordance, or pharmacokinetic effects, such as poor absorption or 
rapid metabolism. Therefore, determining treatment-resistance first requires ensuring 
adequate concordance, by combining measures such as self-report, family report with 
objective measures such as antipsychotic levels and use of long-acting injections. However, 
the optimum measure is showing the drug has reached its target site in the brain at 
adequate levels. Neuroimaging is the best in vivo approach for this.  
The role of neuroimaging in understanding variability in response 
The initial focus of neuroimaging in psychosis was brain structure. Early CT and MRI imaging 
findings showed larger ventricular volume, thought to be secondary to lower levels of grey 
and white matter, was associated with poorer clinical response. In addition, diffusion Tensor 
Imaging (DTI) studies have shown reduced white matter integrity in non-responders 
compared to responders. Generally, structural alterations in non-responders are more 
marked rather than categorically different to brain structure in responders (1). 
Functional Magnetic resonance imaging (fMRI) has also examined response. Resting-state 
fMRI analyses show baseline cortico-striatal functional connectivity associated with 
subsequent antipsychotic response with 80% sensitivity and 75% specificity.  Thus, both 
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functional and structural MR can determine brain changes linked to variation in 
antipsychotic response. However, as mechanism by which these differences might underlie 
response is unclear, we will focus on neurochemical imaging that indexes neurotransmitter 
systems relevant to antipsychotic action. 
What has imaging told us about the biological basis for psychosis? 
Hyperactivity of the subcortical dopamine system is widely thought to underlie the 
development of psychosis, at least in most patients. Involvement of dopamine in the 
pathoetiology of psychosis was initially based on observations that amphetamine congeners 
induce psychosis in healthy people and worsen psychosis in psychotic disorders. However, it 
was not until development of single photon computed tomography  (SPECT) and positron 
emission tomography (PET) that it was possible to show this was linked to dopamine 
release. Meta-analysis of studies of striatal D2/3 receptor density and dopamine transporter 
alterations in schizophrenia show these systems to be unlikely to be altered; In contrast, 
studies show marked elevations in dopamine synthesis capacity and dopamine release to 
amphetamine in schizophrenia, including in antipsychotic free/naïve patients (2). Greater 
dopamine release following amphetamine was directly associated with greater induction of 
psychotic symptoms, indicating dopamine release can induce psychosis. Furthermore, in 
people at high risk of psychosis, there appears to be elevated dopamine synthesis capacity 
in people who develop psychosis, compared to those who do not. Synthesis of this literature 
(incorporating over 40 molecular imaging studies) found an overall large effect size (cohen’s 
d=0.8) elevation in striatal dopamine release and synthesis capacity in schizophrenia 
compared to controls. Thus, excess dopamine synthesis and release seem to drive the 
development and relapse of psychosis. 
 5 
Imaging evidence on how antipsychotic drugs work: receptor occupancy and clinical 
response 
All currently licensed antipsychotics block dopamine D2/3 receptors in-vitro but it was 
unclear whether this was important for their clinical action. SPECT and PET have shown in-
vivo that antipsychotics cross blood-brain barrier, and at clinically effective doses occupy a 
substantial proportion of striatal D2/3 receptors in healthy people and patients. Meta-
analysis of imaging studies in patients shows antipsychotic D2/3 occupancy by antipsychotics 
explains about 25% of clinical response, with the potential exceptions of clozapine and 
quetiapine. The relationship has also been tested prospectively, Kapur et al examining the 
effects of low and moderate dose haloperidol on D2/3 receptors in first episode 
schizophrenia. They found striatal D2/3 occupancy by haloperidol separated responders from 
non-responders: those with occupancy greater than about 65% were more likely to respond 
to antipsychotic treatment (3). Occupancy at serotonin 2A and 1A receptors have also been 
suggested as potentially contributing therapeutic action of some antipsychotics. However, 
imaging studies have not found clear links between occupancy at these receptors and 
variability in response. 
In summary, antipsychotics act to block D2/3 receptors to dampen consequences of excess 
dopaminergic neurotransmission, explaining about 25% of variability in response. This raises 
the question of whether they normalise underlying dopaminergic dysfunction. Recent 
evidence suggests they do not, at least at standard therapeutic doses (4). It also raises the 
questions of what accounts for the remaining variability in response.  
Imaging findings on dopaminergic function in treatment non-responders 
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Whilst it is clear that levels of D2/3 occupancy can explain variability in response to most 
antipsychotics, a key question is whether high occupancy guarantees response. PET and 
SPECT studies showed, despite high D2/3 occupancy, a proportion of patients did not 
significantly respond to treatment; indicating that whilst D2/3 occupancy may be necessary 
for response, it does not guarantee it. Molecular imaging studies therefore examined the 
relationship between the presynaptic dopamine system and antipsychotic response to 
determine if differences in underlying dopaminergic dysfunction accounted for this 
variability. An initial SPECT study used a technique that provides an index of synaptic 
dopamine levels, finding striatal synaptic dopamine positively correlated with subsequent 
antipsychotic response, explaining about 34% of variability in psychotic symptom response. 
Further examination of the presynaptic system in treatment resistant schizophrenia found 
lower striatal dopamine synthesis capacity in treatment resistant illness compared to those 
with schizophrenia whose illness had responded to antipsychotics. This was also found in 
people with treatment resistant illness taking clozapine relative to patients whose 
symptoms responded to first-line antipsychotics. These cross-sectional findings have 
recently been extended in a prospective [18F] -DOPA study in people with first episode 
psychosis, which avoids potential confounds of illness duration and antipsychotic use that 
could have affected prior studies. This found around 40% of response in positive psychotic 
symptoms was explained by initial dopamine synthesis capacity (5). Thus, imaging of 
presynaptic striatal dopaminergic function explains a moderate-large degree of variability in 
response to antipsychotics.  
Imaging findings of glutamatergic function in non-responders 
 7 
The findings discussed above suggest a non-dopaminergic abnormality may underlie 
treatment resistance, raising the question of what underlies psychosis in these patients? 
The field has focused on other neurotransmitter systems, specifically the excitatory 
neurotransmitter glutamate, measured using magnetic resonance spectroscopy (MRS).The 
MRS literature has suggested elevation in anterior cingulate glutamate (specifically the 
glutamate/creatine ratio) as a marker of poor treatment response, in three different 
cohorts, in antipsychotic naïve/minimally-treated first episode schizophrenia, and cohorts 
with established schizophrenia. The degree of variability explained is less than the 
dopaminergic findings above: analysis of antipsychotic naïve participants indicates that 
about 13% of variance in change in total psychotic symptoms (PANSS) was explained by 
Glu/Cr ratio in the anterior cingulate cortex. 
Conclusions and future directions 
In vivo imaging studies show presynaptic dopamine function explains at least a third, and 
D2/3 receptor occupancy about 25%, of variability in response of psychotic symptoms to 
treatment. It remains unknown how much variability they would explain if combined but if, 
as discussed above, treatment resistance is a non-dopaminergic form of psychosis then this 
may not be much more than measured separately. What then explains the remaining 
variability? A proportion of response is related to non-drug effects, reflected in placebo 
response, and therefore it is unlikely these measures will explain all variability in response. 
Notwithstanding this, MRS, functional and structural imaging findings indicate interactions 
with other systems are likely to explain additional variance. This warrants testing in studies 
that combine measures. Studies also need to test sensitivity and specificity of measures to 
identify treatment resistant patients in real world settings, to determine translational 
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potential. Finally, we have focussed on psychosis in schizophrenia where most of the 
evidence lies. However, recent findings suggest the same principles may also apply to 
response in bipolar disorder, which requires further testing. 
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Figure legend; Figure indicating the aetiological role of dopamine in psychosis and action of 
antipsychotic drugs on the dopamine system, with variability of response indicated for 
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